About The Study:

 Crohn’s disease is a chronic inflammatory condition affecting the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, weight loss, and fatigue. Complications may include strictures, fistulas, and nutritional deficiencies. Treatment involves medications and, in some cases, surgery, requiring a personalized approach for effective management and improved quality of life. 

Currently marketed treatments for mild-to-moderate Crohn’s Disease (CD) have significantly improved the care of patients by helping to induce remission and decreasing the need for hospitalization and surgeries, however, these therapies come with safety and side effect concerns and strict safety monitoring requirements exist.  The investigational product in this study has the potential to add value to the treatment of moderate-to-severe CD, especially given lack of effective, safe and well-tolerated oral agents. 

During this study there will be several measures to determine its effectiveness, including endoscopic evaluations (bowel scopes). Health insurance is not required nor needed to participate in this study. 


  • Between the ages of 18-75 years old
  • Have been diagnosed with active moderate to severe Crohn’s Disease at least 30 days ago
  • Are you willing to undergo ileocolonoscopy (bowel scope) with biopsies?
  • Have undergone at least one previous treatment attempt without success.
  • *Please note, other qualifications apply